Radotinib
| Price | $1 |
| Package | 1KG |
| Min. Order: | 1KG |
| Update Time: | 2019-12-26 |
Product Details
| Product Name: Radotinib | CAS No.: 926037-48-1 |
| Min. Order: 1KG | Purity: ≥98% |
| Supply Ability: g/kg/Ton | Release date: 2019/12/26 |
| Delivery Time: Prompt | Packaging: Bottle/Durm/Bag |
| Transportation: By air/Bay Sea/Express |
Heidi 0776
Email:heidi@coreychem.com
▼
▲
Radotinib Basic information
▼
▲
Product Name:
Radotinib
Synonyms:
IY5511;Radotinib;Radotinib HCl;Supect;Radotinib(IY-5511);4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide
CAS:
926037-48-1
MF:
C27H21F3N8O
MW:
530.5038496
EINECS:
Product Categories:
-;Inhibitors
Mol File:
926037-48-1.mol
▼
▲
Radotinib Chemical Properties
▼
▲
density
1.40±0.1 g/cm3(Predicted)
pka
12.94±0.70(Predicted)
▼
▲
Safety Information
▼
▲
▼
▲
MSDS Information
▼
▲
Radotinib Usage And Synthesis
▼
▲
Description
Radotinib, an inhibitor of Bcr–Abl tyrosine kinase,was approved in January 2012 in Korea as a second-line treatment for chronic myeloid leukemia (CML). Radotinib is a TKI with a similar structure to the second-generation TKI, nilotinib, in which a pyridyl group has been replaced with a pyrazinemoiety. The in vitro activity of radotinib against a variety of tumor cell lines is disclosed in an issued patent. Radotinib was significantly more potent than imatinib in all of the cell lines tested. The synthesis of radotinib via amide coupling is described in the patent literature.
Originator
Il-Yang (Korea)
Indications
Radotinib (Supect(R), Il-Yang Pharmaceutical) is a Bcr–Abl inhibitor that was approved in South Korea in 2012 for the treatment of imatinib-resistant CML. Radotinib, which has a terminal 4-(pyridine-2-yl) pyrimidine moiety, was developed based on the previously approved Bcr–Abl inhibitors nilotinib. Radotinib has equivalent efficacy with that of other second-generation Bcr–Abl inhibitors and is well tolerated in chronic-phase CML patients. The lower cost of radotinib compared with other FDA-approved Bcr–Abl inhibitors makes it an attractive alternative for the treatment of CML in developing nations.
Brand name
Supect
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $39.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 |
China- Since: 2014-12-17
- Address: 702, Building 10, East District, National University Science and Technology Park, High tech Zone, Zh
INQUIRY